

IBD THERAPIES PREGNANCY & LACTATION

	Pregnancy	Lactation
Mesalazine	Low risk	Low risk
Sulfasalazine	Low risk	Low risk
Azathioprine	Low risk	Low risk
Mercaptopurine	Low risk	Low risk
Methotrexate	To be avoided	Passes into the milk so recommended to avoid
Infliximab	Low risk	Low risk
Adalimumab	Low risk	Low risk
Golimumab	Low risk	Low risk
Certolizumab	Low risk	Low risk
Vedolizumab	Low risk	Low risk
Ustekinumab	Low risk	Low risk
Risankizumab	No data yet	No data yet
Mirikizumab	No data yet	No data yet
Tofacitinib	No data yet	Passes into the milk & manufacturers recommend to avoid it & at least 18 hours after the last dose
Filgotinib	No data yet	Passes into the milk & exposure to newborn cannot be excluded
Upadacitinib	No data yet	Very little data but likely to apply same concept than to other JAKs and avoidance is recommended
Ozanimod	Scarce data to be avoided	Very little data but the metabolites can be detected in the milk the manufacturers recommend to avoid
Etrasimod	Scarce data to be avoided	Not enough information is available on the use of etrasimod during breastfeeding

ECCO 2022 & AGA 2019 guidelines

Julsgard M et al. Lancet. 2023; 8 (8): 695-697

https://www.ema.europa.eu/en/documents/product-information/zeposia-epar-product-information_en.pdf
https://ec.europa.eu/health/documents/community-register/2019/20191216146604/anx_146604_en.pdf

Low risk

To be avoided

No data yet

No data-recommended to avoid

